PS-C22-2: UNDERSTANDING CLINICAL EFFECTIVENESS OF TELMISARTAN AS MONOTHERAPY FOR HYPERTENSION MANAGEMENT IN NEPAL

Abstract

Background: Telmisartan, a highly selective angiotensin II receptor blocker, approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents and provides full 24-h blood pressure control. It also has established data with respect to long-term efficacy and safety. Objective: The present study aimed to evaluate the clinical effectiveness and safety of telmisartan as monotherapy for the management of patients with hypertension from Nepal. Methods: This was a multicentric, survey analysis conducted in patients aged > 18 years receiving telmisartan as monotherapy for the management of hypertension. Study was conducted between Nov 2020 and Jan 2021. Data was collected during each visit at baseline, day 45, and day 90, from selected clinics/hospitals. Results: A total of 185 patients (mean age, 54.6 years) were included in this study. Out of 185, 139 patients received telmisartan as monotherapy of various dosage patterns. Majority of patients (48.9%) received telmisartan 40 mg followed by telmisartan 60 mg (38.9%) and telmisartan 20 mg (12.2%). Diabetes was the most common comorbid condition observed in 45.9% of patients with hypertension. A significant reduction in the SBP/DBP was observed during the course of telmisartan monotherapy (Figure 1). The mean (95% confidence interval) change in SBP and DBP from baseline to day 45 and day 90 was 16.6 (15.4–17.9); P < 0.001 and 8.6 (7.7–9.5); P < 0.001, 26.0 (24.5–27.5); P < 0.001 and 13.6 (12.5–14.7); P < 0.001, and 9.3 (8.2–10.3); P < 0.001 and 5.0 (4.2–5.9); P < 0.001, respectively. Conclusion: Telmisartan as monotherapy was found to be effective in reducing blood pressure and achieving the blood pressure target in Nepalese patients with hypertension. Conflict of interest: All other authors have nothing to disclose.